drugset / Trial / NCT02927210

Summary

This is a Phase I multicenter, double-blind, single dose, dose-ranging study, in healthy men to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of Dimethandrolone Undecanoate (DMAU) administered as an intramuscular or subcutaneous injection.

Timeline

Start
2017-02-15
Primary completion
2024-11-07
Completion
2025-04-29

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dimethandrolone Undecanoate Unknown 50 mg Intramuscular
Subject Dimethandrolone Undecanoate Unknown 80 mg Intramuscular
Subject Dimethandrolone Undecanoate Unknown 100 mg Intramuscular
Subject Dimethandrolone Undecanoate Unknown 200 mg Intramuscular
Subject Dimethandrolone Undecanoate Unknown 240 mg Intramuscular
Subject Dimethandrolone Undecanoate Unknown 480 mg Intramuscular
Subject Dimethandrolone Undecanoate Unknown 800 mg Intramuscular

Indications

No indication recorded.